LEVONEST Drug Patent Profile

When do Levonest patents expire, and what generic alternatives are available?

Levonest is a drug marketed by Novast Labs Ltd and is included in one NDA.

The generic ingredient in LEVONEST is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.

Summary for LEVONEST

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for LEVONEST

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novast Labs Ltd	LEVONEST	ethinyl estradiol; levonorgestrel	TABLET;ORAL-28	090719-001	Dec 29, 2010	AB	RX	No	No

Investment Scenario and Fundamentals Analysis of LEVONEST

Last updated: February 21, 2026

What is LEVONEST?

LEVONEST, a formulation containing Norethindrone, is used for contraceptive purposes as well as hormone therapy. It is marketed primarily as an oral contraceptive in various regions. The drug's market presence is primarily driven by its established safety profile and brand recognition.

Market Overview and Therapeutic Segment

Global Contraceptive Market

• Estimated value: $22 billion in 2022.
• Compound annual growth rate (CAGR): 4.8% (2023–2028).
• Major players: Bayer, Pfizer, Teva, and local generic manufacturers.
• Key regions: North America, Europe, Asia-Pacific.

Norethindrone Products

• Market share: Approx. 15%–20% of combined oral contraceptive markets.
• Licensing: Many variants available via patent expiry, expanding generic competition.

Regulatory Environment

• Regions such as the US, EU, and Japan have strict regulatory pathways for hormonal contraceptives.
• Post-approval surveillance and manufacturing standards are key compliance factors.

Investment Fundamentals

Patent Status and Generic Competition

• LEVONEST’s active ingredients are off-patent in several territories, prompting entry by generics.
• Patent expirations have historically led to price reductions and market share shifts.
• New formulations or delivery methods (e.g. extended-release, combination pills) may offer differentiation.

Revenue and Pricing Dynamics

Parameter	Current Status	Notes
Estimated annual revenue	$70–$100 million (brand-specific figures, approximate)	Market share dependent; generic expansion impacts
Pricing trend	Declines 5-10% annually post-patent expiry	Market pressure from generics
Market penetration	Moderate in developed markets, emerging in developing regions	Growth potential with awareness campaigns

R&D and Pipeline Prospects

• Limited new indications; primary growth via expanded access and formulations.
• Possible pipeline include lower-dose options or combination therapies to meet regulatory or consumer preferences.
• No significant R&D investments announced recently for LEVONEST directly; focus on existing formulations.

Regulatory and Legal Risks

• Ongoing patent litigations or exclusivity periods can delay generics or new entrants.
• Regulatory hurdles in emerging markets could limit access or increase costs.
• Patent challenges and potential for biosimilar or generic entrants pose risks to profitability.

Manufacturing and Supply Chain Considerations

• Established manufacturing infrastructure aligns with global GMP standards.
• Dependence on raw materials like Norethindrone can introduce supply chain vulnerabilities.
• Supply chain disruptions could impact availability and revenue.

Competitive Landscape

Competitor	Market Share	Product Portfolio	Differentiation Factors
Bayer	Leading	Microgynon, Yasmin	Brand recognition, innovative delivery systems
Teva	Second tier	Generic Norethindrone formulations	Cost leadership, extensive manufacturing network
Pfizer	Significant	Ortho-Novum series	Market coverage, research investments

Market Drivers and Barriers

Drivers

• Rising awareness of contraceptive options.
• Increasing acceptance of hormonal contraception in emerging markets.
• Patent expiries opening pathways for generics.

Barriers

• Stringent regulatory environments.
• Price competition from generics.
• Social and cultural resistance in certain regions.

Strategic Considerations for Investors

• Focus on regions with high growth potential such as Asia-Pacific and Latin America.
• Watch for regulatory changes that could extend exclusivity or accelerate generic entry.
• Monitor innovation trends in hormone therapies that might replace or supplement LEVONEST.

Key Takeaways

• LEVONEST operates in a mature, price-competitive segment with declining revenues due to patent expiries and expanding generic markets.
• Limited pipeline advancement suggests growth will rely on market penetration, price management, and possible formulation innovations.
• The regulatory environment is complex, with potential risks from patent challenges and market access barriers.
• The competitive landscape favors well-established players, but price competition from generics is significant.
• Emerging markets offer growth opportunities through increased acceptance and government family planning initiatives.

FAQs

1. What is the primary revenue driver for LEVONEST?
   The drug’s revenue depends on regional market share, pricing strategies, and the extent of generic competition.

2. How does patent expiry impact LEVONEST’s market?
   Patent expiry typically leads to increased generic entry, reducing prices and market share for the brand.

3. Are there any new formulations for LEVONEST in development?
   No substantial pipeline updates; growth hinges on existing formulations and market expansion.

4. What are the main regulatory risks facing LEVONEST?
   Patent litigation, approval delays for generics, and regulatory restrictions in emerging markets.

5. Which regions present the best growth opportunities for LEVONEST?
   Asia-Pacific and Latin America, driven by demographic trends and family planning policies.

---

References

[1] MarketWatch. (2022). Global contraceptive market analysis.
[2] Grand View Research. (2023). Hormonal contraceptives market report.
[3] U.S. Food and Drug Administration. (2023). Regulatory pathways for hormonal contraceptives.
[4] IQVIA. (2022). Pharmacovigilance and market analytics for hormonal drugs.
[5] Patent databases and industry filings.